Latest Conference Articles

February 19th 2022, 7:24pm

Genitourinary Cancers Symposium (ASCO GU)

A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

February 19th 2022, 6:47pm

Genitourinary Cancers Symposium (ASCO GU)

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

February 19th 2022, 6:30pm

Genitourinary Cancers Symposium (ASCO GU)

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

February 19th 2022, 5:11pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with lenvatinib plus pembrolizumab was associated with a clinical benefit in advanced renal cell carcinoma, regardless of a patient’s biomarker status.

February 19th 2022, 5:00pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.

February 19th 2022, 4:50pm

Genitourinary Cancers Symposium (ASCO GU)

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

February 19th 2022, 4:03pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

February 19th 2022, 4:01pm

Genitourinary Cancers Symposium (ASCO GU)

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

February 19th 2022, 3:51pm

Genitourinary Cancers Symposium (ASCO GU)

Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.

February 18th 2022, 11:15pm

Genitourinary Cancers Symposium (ASCO GU)

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

February 18th 2022, 10:34pm

Genitourinary Cancers Symposium (ASCO GU)

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

February 18th 2022, 10:29pm

Genitourinary Cancers Symposium (ASCO GU)

Avelumab failed to demonstrate an improvement in overall survival at 1 year as frontline treatment in patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer, though it did elicit a notable objective response rate.

February 18th 2022, 10:13pm

Genitourinary Cancers Symposium (ASCO GU)

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

February 18th 2022, 9:10pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.

February 18th 2022, 7:29pm

Genitourinary Cancers Symposium (ASCO GU)

Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.

February 18th 2022, 4:36pm

Genitourinary Cancers Symposium (ASCO GU)

The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate.

February 18th 2022, 2:10pm

Genitourinary Cancers Symposium (ASCO GU)

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

February 18th 2022, 1:04am

Genitourinary Cancers Symposium (ASCO GU)

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone

February 18th 2022, 12:51am

Genitourinary Cancers Symposium (ASCO GU)

The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.

February 17th 2022, 11:49pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.